Next 10 |
home / stock / ntra / ntra articles
On CNBC’s "Halftime Report Final Trades," Amy Raskin of Chevy Chase Trust said Natera, Inc. (NASDAQ: NTRA) has an $11 billion mar...
On Tuesday, Cathie Wood-led Ark Invest adjusted its portfolio, making significant trades. Among these, the firm’s decision to sell $9.3 milli...
Invitae Corporation (NYSE:NVTA), backed by SoftBank Group (OTC:SFTBY) (OTC:SFTBF), is reportedly on the brink of filing for bankrupt...
Shares of DatChat, Inc. (NASDAQ: DATS) fell sharply in pre-market trading after announcing a proposed underwritten public offering of common stock...
U.S. stock futures were lower this morning, with the Dow Jones futures falling more than 100 points on Wednesday. Shares of Progress Software Corp...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
Shares of NeoGenomics Inc (NASDAQ: NEO) fell Thursday after the company received a preliminary injunction from a North Carolina district ...
As of Nov. 17, 2023, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in th...
U.S. stocks traded mostly lower, with the Dow Jones falling around 75 points on Thursday. Here are some big stocks recording gains in today’s...
News, Short Squeeze, Breakout and More Instantly...
ProActive study shows Natera’s Prospera Kidney™ test detects rejection five months before biopsy Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced a new publication from the ProActive study in Transplantation supporting ...
Prospective, multi-center Trifecta-Heart and DTRT-2 studies demonstrate excellent performance of the Prospera Heart test for detecting rejection in adults and pediatrics Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of...
2024-04-05 18:30:02 ET Stephens analyst issues BUY recommendation for NTRA on April 5, 2024 05:00PM ET. The previous analyst recommendation was Buy. NTRA was trading at $96.75 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...